ForPatients
by Roche

Acute Ischemic Stroke Thrombolysis

Tenecteplase in Stroke Patients Between 4 and 24 Hours

Tenecteplase in Stroke Patients Between 4.5 and 24 Hours

Trial Status	Trial Runs In	Trial Identifier
Completed	2 Countries	NCT03785678 ML40787

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This study will evaluate the efficacy and safety of tenecteplase compared with placebo in participants with acute ischemic stroke (AIS). All participants will receive standard-of-care therapy according to AmericanHeart Association/American Stroke Association clinical guidelines (2018). To determine eligibility for randomization, all participants will undergo multimodal CT or MRI at baseline. Only participants with a vessel occlusion (ICA or MCA M1/M2) and penumbral tissue will be randomized. The primary analysis is to compare the efficacy of tenecteplase versus placebo in all participants at Day 90.

Genentech, Inc.
Sponsor

Phase 3
Phase

NCT03785678 ML40787
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	>=18 Years	No